Rapidly loading emicizumab without immunosuppression in acquired haemophilia
- PMID: 37858327
- DOI: 10.1016/S2352-3026(23)00303-4
Rapidly loading emicizumab without immunosuppression in acquired haemophilia
Conflict of interest statement
MVR reports research funding to her institution from BioMarin, Sanofi, SPARK, and Takeda Pharmaceuticals; and service on advisory boards of BeBio, BioMarin, Hemab Therapeutics, Sanofi, SPARK, and Takeda Pharmaceuticals.
Comment on
-
International recommendations on the diagnosis and treatment of acquired hemophilia A.Haematologica. 2020 Jul;105(7):1791-1801. doi: 10.3324/haematol.2019.230771. Epub 2020 May 7. Haematologica. 2020. PMID: 32381574 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
